



October 25, 2019

**BSE Limited**  
P. J. Towers  
Dalal Street, Fort  
**Mumbai - 400 001**

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E),  
**Mumbai - 400 051**

Dear Sirs,

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended September 30, 2019 were approved by the Board of Directors of the Company at its meeting held today at 1.00 p.m. and concluded at 3.40 p.m.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2019;
2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and
3. Copies of the Press Release and Presentation.

We request you to take the same on records.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

Rajiv Shah  
Company Secretary

Encl.: as above

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624

# B S R & Co. LLP

Chartered Accountants

6th Floor, Tower - A, Plot # 07  
Advant Navis Business Park  
Sector - 142, Noida Expressway  
Noida - 201305, UP, (India)


Telephone + 91 120 386 8000  
Fax + 91 120 386 8999

## Limited review report on unaudited quarterly standalone financial results and standalone year-to-date results under Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015

To  
Board of Directors of Jubilant Life Sciences Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Jubilant Life Sciences Limited ("the Company") for the quarter ended 30 September 2019 and year to date results for the period from 1 April 2019 to 30 September 2019 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP  
Chartered Accountants  
ICAI Firm's Registration No. 101248W/W-100022



Gaurav Mahajan  
Partner

Membership No. 507857

UDIN No.: 19507857AAAACN2252

Place: Noida  
Date: 25 October 2019

Jubilant Life Sciences Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)



CIN:L24116UP1978PLC004624

Website: www.jubl.com, Email: investors@jubl.com, Tel: +91-5924-267200, Fax: +91-5924-252352

Statement of Standalone Unaudited Results for the Quarter and Half year ended 30 September 2019

(₹ in Lakhs)



Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2019	2019	2018	2019	2018	2019
1	<b>Revenue from operations</b>						
	a) Sales/Income from operations	74810	77961	87831	152771	169159	339338
	b) Other operating Income	944	1021	896	1965	2732	4523
	<b>Total revenue from operations</b>	<b>75754</b>	<b>78982</b>	<b>88727</b>	<b>154736</b>	<b>171391</b>	<b>343861</b>
2	Other income (refer note 8 below)	7908	594	6380	8502	6821	7800
3	<b>Total income (1+2)</b>	<b>83662</b>	<b>79576</b>	<b>95107</b>	<b>163238</b>	<b>178212</b>	<b>351661</b>
4	<b>Expenses</b>						
	a) Cost of materials consumed	39597	41991	49118	81588	92374	187460
	b) Purchases of stock-in-trade	3162	2734	3986	5896	7604	13147
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1595)	(1080)	583	(2075)	4104	4074
	d) Employee benefits expense	6154	6617	6843	12771	13256	26571
	e) Finance costs	3229	3295	3408	6524	6503	12896
	f) Depreciation and amortization expense	2545	2366	2153	4911	4258	8648
	g) Other expenses:						
	- Power and fuel expense	9635	8628	9037	18263	16577	35828
	- Others	10315	10293	10858	20608	21010	44094
	<b>Total expenses</b>	<b>73042</b>	<b>74844</b>	<b>85986</b>	<b>147886</b>	<b>165746</b>	<b>333318</b>
5	<b>Profit before exceptional items and tax (3-4)</b>	<b>10620</b>	<b>4732</b>	<b>9121</b>	<b>15352</b>	<b>12466</b>	<b>18343</b>
6	Exceptional items	-	-	-	-	-	-
7	<b>Profit before tax (5-6)</b>	<b>10620</b>	<b>4732</b>	<b>9121</b>	<b>15352</b>	<b>12466</b>	<b>18343</b>
8	Tax expense (refer note 6 below)	(3687)	1506	1160	(2181)	2117	3580
9	<b>Net Profit for the period (7-8)</b>	<b>14307</b>	<b>3226</b>	<b>7961</b>	<b>17533</b>	<b>10349</b>	<b>14763</b>
10	<b>Other Comprehensive Income (OCI)</b>						
	i) a) Items that will not be reclassified to profit or loss	(47)	(47)	(60)	(94)	(119)	(116)
	b) Income tax relating to items that will not be reclassified to profit or loss	17	16	21	33	42	59
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
11	<b>Total Comprehensive Income for the period (9+10)</b>	<b>14277</b>	<b>3195</b>	<b>7922</b>	<b>17472</b>	<b>10272</b>	<b>14706</b>
12	Earnings per share of ₹ 1 each (not annualized)						
	Basic (₹)	8.98	2.03	5.00	11.01	6.50	9.27
	Diluted (₹)	8.98	2.03	5.00	11.01	6.50	9.27
13	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1593	1593	1593	1593
14	Paid-up debt capital#				74500	84500	74500
15	Reserves (excluding Revaluation Reserve)				241490	228003	232438
16	Capital Redemption Reserve				99	99	99
17	Debenture Redemption Reserve				13008	7492	13008
18	Net Worth				243083	229596	234031
19	Debt Equity Ratio#				0.66	0.66	0.71
20	Debt Service Coverage Ratio#				4.11	3.57	3.09
21	Interest Service Coverage Ratio#				4.11	3.57	3.09
	# refer note 3 for definitions						
	See accompanying notes to the Standalone Unaudited Results						



**Jubilant Life Sciences Limited**  
**Statement of Standalone Unaudited Assets and Liabilities**

(₹ in Lakhs)



Sr. No.	Particulars	As at	As at
		30 September	31 March
		(Unaudited)	(Audited)
		2019	2019
<b>A</b>	<b>ASSETS</b>		
1.	<b>Non-current assets</b>		
	Property, plant and equipment	173145	148791
	Capital work-in-progress	10118	28382
	Other intangible assets	493	345
	Intangible assets under development	72	-
	Right of use assets	6984	-
	<b>Financial assets:</b>		
	Investments	176389	176389
	Loans	430	329
	Other financial assets	-	50
	Deferred tax assets (net)	932	-
	Income tax assets (net)	998	1296
	Other non-current assets	239	2664
	<b>Total non-current assets</b>	<b>369800</b>	<b>358246</b>
2.	<b>Current assets</b>		
	Inventories	52068	49194
	<b>Financial assets:</b>		
	Trade receivables	41848	48052
	Cash and cash equivalents	10474	1870
	Other bank balances	2614	1604
	Loans	571	318
	Other financial assets	4393	5982
	Other current assets	18602	21097
	<b>Total current assets</b>	<b>130570</b>	<b>128117</b>
	<b>Total assets</b>	<b>500370</b>	<b>486363</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
1.	<b>Equity</b>		
	Equity share capital	1593	1593
	Other equity	241490	232438
	<b>Total equity</b>	<b>243083</b>	<b>234031</b>
2.	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	<b>Financial liabilities:</b>		
	Borrowings	118111	113957
	Provisions	6319	6196
	Deferred tax liabilities (net)	-	2405
	<b>Total non-current liabilities</b>	<b>124430</b>	<b>122558</b>
	<b>Current liabilities</b>		
	<b>Financial liabilities:</b>		
	Borrowings	33795	46271
	Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	1245	603
	Total outstanding dues of creditors other than micro enterprises and small enterprises	56399	59002
	Other financial liabilities	34922	19613
	Other current liabilities	2254	1815
	Provisions	2122	2078
	Current tax liabilities (net)	2120	392
	<b>Total current liabilities</b>	<b>132857</b>	<b>129774</b>
	<b>Total equity and liabilities</b>	<b>500370</b>	<b>486363</b>



**Jubilant Life Sciences Limited**  
**Note 1: Statement of Standalone Unaudited Cash Flows**

(₹ in Lakhs)

Particulars	Half Year Ended	
	30 September	30 September
	(Unaudited)	(Unaudited)
	2019	2018
<b>A. Cash flow from operating activities</b>		
Operating cash flow before working capital changes	19394	17880
Working capital changes	3795	(14985)
<b>Cash generated from operations</b>	<b>23189</b>	<b>2895</b>
Income tax paid (net of refund)	(576)	(837)
<b>Net cash generated from operating activities</b>	<b>22613</b>	<b>2058</b>
<b>B. Cash flow from investing activities</b>		
Purchase of property, plant and equipment, other intangible assets (including capital work-in-progress and intangible asset under development)	(11128)	(11744)
Movement in other bank balances	(960)	(1532)
Others	7587	6742
<b>Net cash used in investing activities</b>	<b>(4501)</b>	<b>(6534)</b>
<b>C. Cash flow from financing activities</b>		
Proceeds from long term borrowings	-	34824
Repayment of long term borrowings	(16054)	(24779)
(Repayment of) / proceeds from short term borrowings (net)	(15476)	6948
Loans taken from subsidiaries	25725	500
Finance costs paid	(6656)	(6391)
Others	2953	(1114)
<b>Net cash (used in) / generated from financing activities</b>	<b>(9508)</b>	<b>9988</b>
<b>Net increase in cash and cash equivalents (A+B+C)</b>	<b>8604</b>	<b>5512</b>
Add: cash and cash equivalents at the beginning of the period	1870	3647
<b>Cash and cash equivalents at the end of the period</b>	<b>10474</b>	<b>9159</b>




## Jubilant Life Sciences Limited

Note 2: Standalone Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Half year ended 30 September 2019

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2019	2019	2018	2019	2018	2019
<b>1</b>	<b>Segment revenue</b>						
	a. Life Sciences Ingredients	74990	78214	88097	153204	170160	341386
	b. Pharmaceuticals	764	768	630	1532	1231	2475
	<b>Total</b>	<b>75754</b>	<b>78982</b>	<b>88727</b>	<b>154736</b>	<b>171391</b>	<b>343861</b>
	Less : Inter segment revenue	-	-	-	-	-	-
	<b>Total revenue from operations</b>	<b>75754</b>	<b>78982</b>	<b>88727</b>	<b>154736</b>	<b>171391</b>	<b>343861</b>
	a. Life Sciences Ingredients	74990	78214	88097	153204	170160	341386
	b. Pharmaceuticals	764	768	630	1532	1231	2475
	<b>Total</b>	<b>75754</b>	<b>78982</b>	<b>88727</b>	<b>154736</b>	<b>171391</b>	<b>343861</b>
<b>2</b>	<b>Segment results (profit(+)/loss(-) before tax, exceptional items and interest from each segment)</b>						
	a. Life Sciences Ingredients	6457	8961	7523	15418	14889	29549
	b. Pharmaceuticals	(321)	(151)	(382)	(472)	(693)	(1367)
	<b>Total</b>	<b>6136</b>	<b>8810</b>	<b>7141</b>	<b>14946</b>	<b>14196</b>	<b>28182</b>
	Less : i. Interest (Finance costs)	3229	3295	3408	6524	6503	12896
	ii. Exceptional item and un-allocable expenditure (net of un-allocable income)	(7713)	783	(5388)	(6930)	(4773)	(3057)
	<b>Profit before tax</b>	<b>10620</b>	<b>4732</b>	<b>9121</b>	<b>15352</b>	<b>12466</b>	<b>18343</b>
<b>3</b>	<b>Segment assets</b>						
	a. Life Sciences Ingredients	292342	293780	282328	292342	282328	287642
	b. Pharmaceuticals	701	938	725	701	725	568
	c. Unallocable corporate assets	207327	199060	195676	207327	195676	198153
	<b>Total Segment assets</b>	<b>500370</b>	<b>493778</b>	<b>478729</b>	<b>500370</b>	<b>478729</b>	<b>486363</b>
<b>4</b>	<b>Segment liabilities</b>						
	a. Life Sciences Ingredients	69708	69675	73653	69708	73653	73305
	b. Pharmaceuticals	810	752	923	810	923	637
	c. Unallocable corporate liabilities	186769	186126	174557	186769	174557	178390
	<b>Total Segment liabilities</b>	<b>257287</b>	<b>256553</b>	<b>249133</b>	<b>257287</b>	<b>249133</b>	<b>252332</b>



3. The Secured Rated Listed Redeemable Non-Convertible Debentures (NCDs) aggregating to ₹ 74500 lakhs outstanding as at 30 September 2019 are secured by a first pari-passu charge created by way of mortgage on certain immovable assets and hypothecation on entire movable fixed assets, both present and future, of the Company. On 15 October 2019, India Ratings and Research Private Limited affirmed the rating of both NCDs with outstanding of ₹ 39500 lakhs and ₹ 35000 lakhs to "IND AA/ Stable". On 1 July 2019, Crisil Limited reaffirmed the rating of "CRISIL AA/ Stable" to the NCDs with outstanding of ₹ 35000 lakhs. The asset cover thereof based on agreed methodology exceeds 100% of the outstanding principal amount of the said NCDs.

Details of due dates for payment of interest and repayment of principal of NCDs are as follows:

Particulars	Previous Due Date		Next Due Date	
	Principal	Interest	Principal	Interest
1000 – 8.47% Non - Convertible Debentures of ₹ 10 lakhs each	-	27 July 2019	27 January 2020	27 January 2020
1500 – 8.65% Non - Convertible Debentures of ₹ 10 lakhs each	-	27 July 2019	27 January 2021	27 January 2020
1450 – 8.88% Non - Convertible Debentures of ₹ 10 lakhs each	-	27 July 2019	27 January 2022	27 January 2020
1000 – 8.95% Non - Convertible Debentures of ₹ 10 lakhs each	-	5 September 2019	5 September 2020	5 March 2020
1000 – 9.10% Non - Convertible Debentures of ₹ 10 lakhs each	-	5 September 2019	5 September 2021	5 March 2020
1500 – 9.26% Non - Convertible Debentures of ₹ 10 lakhs each	-	5 September 2019	5 September 2022	5 March 2020

Interest due on 27 July 2019 and 5 September 2019 has been paid on the due date.

Definition for ratios:

a) Paid-up debt capital: Secured Rated Listed Redeemable Non-Convertible Debentures (Gross of debt initiation cost)

b) Debt Equity Ratio: Net debts/net worth

(Net debts: Long term borrowings (including current maturities and gross of debt initiation cost) + short term borrowings - cash and cash equivalents - other bank balance - investment in mutual funds)

c) Debt Service Coverage Ratio: EBITDA/(finance costs + scheduled principal repayments (net of refinancing) during the period for long-term debts)

(EBITDA: Profit before tax + depreciation and amortization expense + finance costs and exceptional items)

d) Interest Service Coverage Ratio: EBITDA/finance costs

4. India Branded Pharmaceuticals Business, earlier presented under segment "Others" has now been reclassified under "Pharmaceuticals" segment.

5. The Board of Directors of the Company at its meeting held on 25 October 2019 approved the Composite Scheme of Arrangement for amalgamation of certain promoter shareholding companies into the Company and Demerger of the Life Science Ingredients business into the Resulting entity which will be listed on National Stock Exchange and BSE with a mirror shareholding of the Company.

6. During the quarter, in accordance with Taxation Laws (Amendment) Ordinance, 2019, the Company has evaluated the outstanding net deferred tax liability as at 31 March 2019, and based on current estimates, has written back an amount to the extent of ₹ 5001 lakhs to the Statement of Profit and Loss.

7. Effective from 1 April 2019, the Company has adopted Ind AS 116 - Leases, using the modified retrospective method. The adoption of the standard did not have any material impact to the financial results of the Company.

8. Other income for the quarters ended 30 September 2019, 30 September 2018, half year ended 30 September 2019, 30 September 2018 and year ended 31 March 2019 include ₹ 7417 lakhs, ₹ 5929 lakhs, ₹ 7417 lakhs, ₹ 5929 lakhs and ₹ 5929 lakhs respectively, dividend received from Jubilant Pharma Limited, a wholly owned subsidiary of the Company.

9. Previous period figures have been regrouped / reclassified to conform to the current period's classification.

10. The above standalone unaudited results were, subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 25 October 2019. The review report of the Statutory Auditors is being filed with the BSE and National Stock Exchange. For more details on standalone unaudited results, visit Investors section of our website at [www.jubl.com](http://www.jubl.com) and Financial Results at Corporates section of [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).


For Jubilant Life Sciences Limited



Hari S. Bhartia  
Co-Chairman & Managing Director

Place : Noida

Date : 25 October 2019



# B S R & Co. LLP

Chartered Accountants

6th Floor, Tower - A, Plot # 07  
Advant Navis Business Park  
Sector - 142, Noida Expressway  
Noida - 201305, UP, (India)

Telephone + 91 120 386 8000  
Fax + 91 120 386 8999

## Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results under Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015

To

Board of Directors of Jubilant Life Sciences Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Jubilant Life Sciences Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended 30 September 2019 and year to date results for the period from 1 April 2019 to 30 September 2019 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
  - 1) Jubilant Pharma Limited
  - 2) Draximage Limited, Cyprus
  - 3) Draximage Limited, Ireland
  - 4) Jubilant Draximage (USA) Inc.
  - 5) Jubilant Draximage Inc.
  - 6) 6981364 Canada Inc.
  - 7) Draximage (UK) Limited





- 8) Jubilant Pharma Holdings Inc.
  - 9) Jubilant Clinsys Inc.
  - 10) Cadista Holdings Inc.
  - 11) Jubilant Cadista Pharmaceuticals Inc.
  - 12) Jubilant Life Sciences International Pte. Limited
  - 13) HSL Holdings Inc.
  - 14) Jubilant HollisterStier LLC
  - 15) Jubilant Life Sciences (Shanghai) Limited
  - 16) Jubilant Pharma NV
  - 17) Jubilant Pharmaceuticals NV
  - 18) PSI Supply NV
  - 19) Jubilant Life Sciences (USA) Inc.
  - 20) Jubilant Life Sciences (BVI) Limited
  - 21) Jubilant Biosys (BVI) Limited
  - 22) Jubilant Biosys (Singapore) Pte. Limited
  - 23) Jubilant Biosys Limited
  - 24) Jubilant Discovery Services LLC
  - 25) Jubilant Drug Development Pte. Limited
  - 26) Jubilant Chemsys Limited
  - 27) Jubilant Clinsys Limited
  - 28) Jubilant Infrastructure Limited
  - 29) Jubilant First Trust Healthcare Limited
  - 30) Jubilant Innovation Pte. Limited
  - 31) Jubilant Draximage Limited
  - 32) Jubilant Innovation (India) Limited
  - 33) Jubilant Innovation (USA) Inc.
  - 34) Jubilant HollisterStier Inc.
  - 35) Draxis Pharma LLC
  - 36) Drug Discovery and Development Solutions Limited
  - 37) TrialStat Solutions Inc.
  - 38) Jubilant HollisterStier General Partnership
  - 39) Draximage General Partnership
  - 40) Vanthys Pharmaceutical Development Private Limited
  - 41) Jubilant Generics Limited
  - 42) Jubilant Life Sciences NV
  - 43) Jubilant Pharma Australia Pty Limited
  - 44) Jubilant Draximage Radiopharmacies Inc.
  - 45) Jubilant Pharma SA PTY. Ltd
  - 46) Jubilant Therapeutics India Ltd
  - 47) Jubilant Therapeutics Inc.
  - 48) Jubilant Business Services Limited
  - 49) Jubilant Episcribe LLC
  - 50) Jubilant Prodel, LLC
  - 51) Jubilant Epipad LLC
  - 52) Jubilant Epicore LLC
  - 53) Jubilant Employee Welfare Trust
  - 54) Jubilant Pharma UK Limited (with effect from 17 April 2019)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the Listing



**B S R & Co. LLP**

Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*For B S R & Co. LLP*

*Chartered Accountants*

ICAI Firm's Registration No. 101248W/W-100022



**Gaurav Mahajan**

*Partner*

Membership No.507857

UDIN No.: 19507857AAAACM3816

Place: Noida

Date: 25 October 2019

**Jubilant Life Sciences Limited**

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)



CIN:L24116UP1978PLC004624

Website: www.jubl.com, Email: investors@jubl.com, Tel: +91-5924-267200, Fax: +91-5924-252352

**Statement of Consolidated Unaudited Results for the Quarter and Half year ended 30 September 2019**

(₹ in Lakhs)


Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2019	2019	2018	2019	2018	2019
<b>1</b>	<b>Revenue from operations</b>						
	a) Sales/Income from operations	223655	215278	224557	438933	429186	899709
	b) Other operating income	7938	7908	7397	5846	5678	11373
	<b>Total revenue from operations</b>	<b>226593</b>	<b>218186</b>	<b>226949</b>	<b>444779</b>	<b>434814</b>	<b>911082</b>
<b>2</b>	Other income	1226	970	383	2196	1330	3574
<b>3</b>	<b>Total income (1+2)</b>	<b>227819</b>	<b>219156</b>	<b>227332</b>	<b>446975</b>	<b>436144</b>	<b>914656</b>
<b>4</b>	<b>Expenses</b>						
	a) Cost of materials consumed	77910	78260	83213	156170	161452	328280
	b) Purchases of stock-in-trade	5540	4957	7140	10497	13051	24091
	c) Changes in inventories of finished goods, stock-in-trade and work-in progress	(6127)	(7702)	(2638)	(13829)	(7164)	(187)
	d) Employee benefits expense	52219	50413	47796	102632	92954	192596
	e) Finance costs	7164	7258	5427	14422	10509	21981
	f) Depreciation and amortization expense	11684	10269	8948	21953	17748	37090
	g) Other expenses:						
	- Power and fuel expense	12480	11199	11907	23679	21877	46638
	- Others	37726	37599	34513	75325	63866	145763
	<b>Total expenses</b>	<b>198596</b>	<b>192253</b>	<b>196306</b>	<b>390849</b>	<b>374293</b>	<b>796252</b>
<b>5</b>	<b>Profit before exceptional items and tax (3-4)</b>	<b>29223</b>	<b>26903</b>	<b>31026</b>	<b>56126</b>	<b>61851</b>	<b>118404</b>
<b>6</b>	Exceptional items	-	-	845	-	3033	28023
<b>7</b>	<b>Profit before tax (5-6)</b>	<b>29223</b>	<b>26903</b>	<b>30181</b>	<b>56126</b>	<b>58818</b>	<b>90381</b>
<b>8</b>	Tax expense (refer note 7 below)	4284	8405	9204	12689	17804	32680
<b>9</b>	<b>Net Profit for the period (7-8)</b>	<b>24939</b>	<b>18498</b>	<b>20977</b>	<b>43437</b>	<b>41014</b>	<b>57701</b>
<b>10</b>	<b>Other Comprehensive Income (OCI)</b>						
	i) a) Items that will not be reclassified to profit or loss	(42)	(112)	(108)	(154)	(235)	(795)
	b) Income tax relating to items that will not be reclassified to profit or loss	15	14	12	29	34	51
	ii) a) Items that will be reclassified to profit or loss	2482	4666	14190	7148	15660	(634)
	b) Income tax relating to items that will be reclassified to profit or loss	(74)	137	-	63	-	-
<b>11</b>	<b>Total Comprehensive Income for the period (9+10)</b>	<b>27320</b>	<b>23203</b>	<b>35071</b>	<b>50523</b>	<b>56473</b>	<b>56323</b>
	<b>Net Profit / (Loss) attributable to:</b>						
	Owners of the Company	24939	18498	21041	43437	41291	57446
	Non-controlling Interest	-	-	(64)	-	(277)	255
	<b>Other Comprehensive Income attributable to:</b>						
	Owners of the Company	2381	4705	14094	7086	15460	(1377)
	Non-controlling Interest	-	-	-	-	(1)	(1)
	<b>Total Comprehensive Income attributable to:</b>						
	Owners of the Company	27320	23203	35135	50523	56751	56069
	Non-controlling Interest	-	-	(64)	-	(278)	254
<b>12</b>	Earnings per share of ₹ 1 each (not annualized)						
	Basic (₹)	15.66	11.61	13.50	27.27	26.50	36.86
	Diluted (₹)	15.66	11.61	13.50	27.27	26.50	36.86
<b>13</b>	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1558	1593	1558	1593
<b>14</b>	Paid-up debt capital#				428900	301970	420300
<b>15</b>	Reserves (excluding Revaluation Reserve)				521437	458349	479299
<b>16</b>	Capital Redemption Reserve				3984	3984	3984
<b>17</b>	Debenture Redemption Reserve				13008	7492	13008
<b>18</b>	Net Worth				523030	454477	480902
<b>19</b>	Debt Equity Ratio#				0.65	0.76	0.73
<b>20</b>	Debt Service Coverage Ratio#				6.41	6.65	8.07
<b>21</b>	Interest Service Coverage Ratio#				6.41	6.65	8.07
	# refer note 3 for definitions						
	See accompanying notes to the Consolidated Unaudited Results						



**Jubilant Life Sciences Limited**  
**Statement of Consolidated Unaudited Asset and Liabilities**

(₹ in Lakhs)



Sr. No.	Particulars	As at	As at
		30 September	31 March
		(Unaudited)	(Audited)
		2019	2019
<b>A</b>	<b>ASSETS</b>		
<b>1.</b>	<b>Non-current assets</b>		
	Property, plant and equipment	371387	339621
	Capital work in progress	32888	49160
	Goodwill	201520	195894
	Other intangible assets	26792	29323
	Intangible assets under development	44612	40982
	Right of use assets	14319	-
	<b>Financial assets:</b>		
	Investments	11575	11511
	Loans	1696	1556
	Other financial assets	13	63
	Deferred tax assets (net)	14765	14955
	Income tax assets (net)	3167	3135
	Other non-current assets	4120	2171
	<b>Total non-current assets</b>	<b>726854</b>	<b>688371</b>
<b>2.</b>	<b>Current assets</b>		
	Inventories	164429	141739
	<b>Financial assets:</b>		
	Trade receivables	109610	127155
	Cash and cash equivalents	115715	100540
	Other bank balances	20632	36501
	Loans	406	368
	Other financial assets	8831	10691
	Income tax assets (net)	648	117
	Other current assets	42132	41369
	<b>Total current assets</b>	<b>462403</b>	<b>458480</b>
	<b>Total assets</b>	<b>1189257</b>	<b>1146851</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1.</b>	<b>Equity</b>		
	Equity share capital	1593	1593
	Other equity	521437	479299
	<b>Total equity attributable to equity holders</b>	<b>523030</b>	<b>480892</b>
<b>2.</b>	<b>Non-controlling interest</b>	-	10
	<b>Total equity</b>	<b>523030</b>	<b>480902</b>
<b>3.</b>	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	<b>Financial liabilities:</b>		
	Borrowings	418253	424289
	Other financial liabilities	35	45
	Provisions	11832	11435
	Deferred tax liabilities (net)	21459	20235
	Other non-current liabilities	962	972
	<b>Total non-current liabilities</b>	<b>452541</b>	<b>456976</b>
	<b>Current liabilities</b>		
	<b>Financial liabilities:</b>		
	Borrowings	30525	49971
	Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	1719	1058
	Total outstanding dues of creditors other than micro enterprises and small enterprises	103253	100955
	Other financial liabilities	57391	39540
	Other current liabilities	10148	7817
	Provisions	7282	6874
	Current tax liabilities (net)	3368	2758
	<b>Total current liabilities</b>	<b>213686</b>	<b>208973</b>
	<b>Total equity and liabilities</b>	<b>1189257</b>	<b>1146851</b>



**Jubilant Life Sciences Limited**  
**Note 1: Statement of Consolidated Unaudited Cash Flows**

(₹ in Lakhs)


Particulars	Half Year Ended	
	30 September	30 September
	(Unaudited)	(Unaudited)
	2019	2018
<b>A. Cash flow from operating activities</b>		
<b>Operating cash flow before working capital changes</b>	<b>90920</b>	<b>90174</b>
Working capital changes	(6045)	(22966)
<b>Cash generated from operations</b>	<b>84875</b>	<b>67208</b>
Income tax paid (net of refund)	(12985)	(16906)
<b>Net cash generated from operating activities</b>	<b>71890</b>	<b>50302</b>
<b>B. Cash flow from investing activities</b>		
Purchase of property, plant and equipment, other intangible assets (including capital work-in-progress and intangible asset under development)	(25054)	(30481)
Movement in other bank balances	16526	(1511)
Others	1746	(416)
<b>Net cash used in investing activities</b>	<b>(6782)</b>	<b>(32408)</b>
<b>C. Cash flow from financing activities</b>		
Proceeds from long term borrowings	-	34824
Repayment of long term borrowings	(18149)	(26755)
(Repayment of) / proceeds from short term borrowings (net)	(19446)	7632
Finance costs paid	(15389)	(10240)
Others	(124)	(699)
<b>Net cash (used in) / generated from financing activities</b>	<b>(53108)</b>	<b>4762</b>
<b>D. Effect of exchange rate changes</b>	<b>3175</b>	<b>3281</b>
<b>Net increase in cash and cash equivalents (A+B+C+D)</b>	<b>15175</b>	<b>25937</b>
Add: cash and cash equivalents at the beginning of the period	100540	24418
<b>Cash and cash equivalents at the end of the period</b>	<b>115715</b>	<b>50355</b>



**Jubilant Life Sciences Limited**

Note2: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Half year ended 30 September 2019

Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30 September	30 June	30 September	30 September	30 September	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2019	2019	2018	2019	2018	2019
<b>1</b>	<b>Segment revenue</b>						
	a. Pharmaceuticals	145223	132846	133193	278069	251920	534876
	b. Life Sciences Ingredients	75318	80679	88969	155997	173896	355331
	c. Others	6157	4832	5089	10989	9567	21848
	<b>Total</b>	<b>226698</b>	<b>218357</b>	<b>227251</b>	<b>445055</b>	<b>435383</b>	<b>912055</b>
	Less : Inter segment revenue	105	171	302	276	569	973
	<b>Total revenue from operations</b>	<b>228593</b>	<b>218186</b>	<b>226949</b>	<b>444779</b>	<b>434814</b>	<b>911082</b>
	a. Pharmaceuticals	145223	132846	133193	278069	251920	534876
	b. Life Sciences Ingredients	75303	80549	88717	155852	173401	354523
	c. Others	6067	4791	5039	10858	9493	21683
	<b>Total</b>	<b>226593</b>	<b>218186</b>	<b>226949</b>	<b>444779</b>	<b>434814</b>	<b>911082</b>
<b>2</b>	<b>Segment results (profit(+)/loss(-) before tax, exceptional items and interest from each segment)</b>						
	a. Pharmaceuticals	30888	25511	29619	56399	57179	110329
	b. Life Sciences Ingredients	5568	9805	8660	15373	17432	35564
	c. Others	961	521	630	1482	985	983
	<b>Total</b>	<b>37417</b>	<b>35837</b>	<b>38909</b>	<b>73254</b>	<b>75596</b>	<b>146876</b>
	Less : i. Interest (Finance costs)	7164	7258	5427	14422	10509	21981
	ii. Exceptional items and un-allocable expenditure (net of un-allocable income)	1030	1676	3301	2706	6269	34514
	<b>Profit before tax</b>	<b>29223</b>	<b>26903</b>	<b>30181</b>	<b>56126</b>	<b>58818</b>	<b>90381</b>
<b>3</b>	<b>Segment assets</b>						
	a. Pharmaceuticals	804197	791201	701600	804197	701600	746651
	b. Life Sciences Ingredients	314472	317271	306240	314472	306240	314466
	c. Others	24899	23412	18024	24899	18024	23016
	d. Unallocable corporate assets	45689	38126	40833	45689	40833	62718
	<b>Total Segment assets</b>	<b>1189257</b>	<b>1170010</b>	<b>1066697</b>	<b>1189257</b>	<b>1066697</b>	<b>1146851</b>
<b>4</b>	<b>Segment liabilities</b>						
	a. Pharmaceuticals	78377	83163	71872	78377	71872	70359
	b. Life Sciences Ingredients	70196	70743	74892	70196	74892	74822
	c. Others	4042	3695	3501	4042	3501	3660
	d. Unallocable corporate liabilities	513612	508288	461955	513612	461955	517108
	<b>Total Segment liabilities</b>	<b>666227</b>	<b>665889</b>	<b>612220</b>	<b>666227</b>	<b>612220</b>	<b>665949</b>



3. The Secured Rated Listed Redeemable Non-Convertible Debentures (NCDs) aggregating to ₹ 74500 lakhs outstanding as at 30 September 2019 are secured by a first pari-passu charge created by way of mortgage on certain immovable assets and hypothecation on entire movable fixed assets, both present and future, of the Company. On 15 October 2019, India Ratings and Research Private Limited affirmed the rating of both NCDs with outstanding of ₹ 39500 lakhs and ₹ 35000 lakhs to "IND AA/ Stable". On 1 July 2019, Crisil Limited reaffirmed the rating of "CRISIL AA/ Stable" to the NCDs with outstanding of ₹ 35000 lakhs. The asset cover thereof based on agreed methodology exceeds 100% of the outstanding principal amount of the said NCDs.

Details of due dates for payment of interest and repayment of principal of NCDs are as follows:

Particulars	Previous Due Date		Next Due Date	
	Principal	Interest	Principal	Interest
1000 – 8.47% Non - Convertible Debentures of ₹ 10 lakhs each	-	27 July 2019	27 January 2020	27 January 2020
1500 – 8.65% Non - Convertible Debentures of ₹ 10 lakhs each	-	27 July 2019	27 January 2021	27 January 2020
1450 – 8.88% Non - Convertible Debentures of ₹ 10 lakhs each	-	27 July 2019	27 January 2022	27 January 2020
1000 – 8.95% Non - Convertible Debentures of ₹ 10 lakhs each	-	5 September 2019	5 September 2020	5 March 2020
1000 – 9.10% Non - Convertible Debentures of ₹ 10 lakhs each	-	5 September 2019	5 September 2021	5 March 2020
1500 – 9.26% Non - Convertible Debentures of ₹ 10 lakhs each	-	5 September 2019	5 September 2022	5 March 2020

Interest due on 27 July 2019 and 5 September 2019 has been paid on the due date.

Definition for ratios:

- Paid-up debt capital: Secured Rated Listed Redeemable Non-Convertible Debentures issued by the Company and unsecured high yield bonds issued by Jubilant Pharma Limited ("JPL"), Singapore, a wholly-owned subsidiary of the Company (Gross of debt initiation cost).
- Debt Equity Ratio: Net debts/net worth  
{Net debts: Long term borrowings (including current maturities and gross of debt initiation cost) + short term borrowings - cash and cash equivalents - other bank balances - investment in mutual funds}  
{Net worth including non-controlling interest}
- Debt Service Coverage Ratio: EBITDA/{finance costs + scheduled principal repayments (net of refinancing) during the period for long-term debts}  
{EBITDA: Profit before tax + depreciation and amortization expense + finance costs + exceptional items}
- Interest Service Coverage Ratio: EBITDA/finance costs

4. Jubilant Pharma Limited ("JPL"), a wholly owned subsidiary of the Company has elected to exercise its option to redeem US\$ 100 million in aggregate principal amount of the Notes (US\$ 300 million 4.875% Senior Notes due 2021) on 20 November 2019. The Notes will be redeemed on a pro-rata basis as per the terms of the indenture and will be cancelled upon redemption by JPL.

5. India Branded Pharmaceuticals Business, earlier presented under segment "Others" has now been reclassified under "Pharmaceuticals" segment.

6. The Board of Directors of the Company at its meeting held on 25 October 2019 approved the Composite Scheme of Arrangement for amalgamation of certain promoter shareholding companies into the Company and Demerger of the Life Science Ingredients business into the Resulting entity which will be listed on National Stock Exchange and BSE with a mirror shareholding of the Company.

7. During the quarter, in accordance with Taxation Laws (Amendment) Ordinance, 2019, the Company has evaluated the outstanding net deferred tax liability as at 31 March 2019, and based on current estimates, has written back an amount to the extent of ₹ 5001 lakhs to the Statement of Profit and Loss.

8. Effective from 1 April 2019, the Group has adopted Ind AS 116 - Leases, using the modified retrospective method. The adoption of the standard did not have any material impact to the financial results of the Group.

9. Previous period figures have been regrouped / reclassified to conform to the current period's classification.



10. The above consolidated unaudited results were, subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 25 October 2019. The review report of the Statutory Auditors is being filed with the BSE and National Stock Exchange. For more details on consolidated unaudited results, visit Investors section of our website at www.jubl.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Life Sciences Limited



Hari S. Bhartia  
Co-Chairman & Managing Director

Place : Noida  
Date : 25 October 2019



**PRESS RELEASE**

**Noida, Monday, Oct 25, 2019**

## **JUBILANT LIFE SCIENCES – Q2 & H1'FY20 RESULTS**

---

- Revenue flat at Rs. 2,266 Crore vs. Q2'FY19; EBITDA at Rs 481 Crore up 6% YoY and 8% QoQ
- PAT at Rs 249 Crore up 19% YoY and 35% QoQ with EPS of Rs. 15.7 per share vs. Rs 13.5 per share last year

The Board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company met today to approve financial results for the quarter ended September 30, 2019.

**Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said:**

"We witnessed steady performance in revenue and improvement in operating profits in Q2'FY20 both on a YoY basis and sequentially.

Pharmaceutical segment revenues grew 9% both in YoY and QoQ, led by growth in all key businesses. EBITDA growth of 7% YoY and 17% QoQ with margin at 26.6%. Adjusted EBITDA of Pharmaceutical segment was 11% higher YoY with a margin of 28.1% after adjusting for one-off expenses of Rs 23 Crore related to site remediation and litigation expenses.

In the Life Science Ingredients (LSI) segment while we witnessed good growth in Specialty Intermediates and Nutritional Products businesses, the overall revenue was down 15% YoY due to lower input prices of acetic acid and higher molasses prices in the Life Sciences Chemical business.

The Drug Discovery Services business grew 20%. In view of the strong demand being witnessed, we are making significant investments in this business to double capacities over the next 2-3 years.

Our Proprietary Drug Discovery business under Jubilant Therapeutics is a semi virtual biopharma business. We are currently working on seven programs targeting small molecule therapies in the area of oncology and auto-immune disorders with potential to fast track promising assets from discovery to clinical stage.

Demand conditions for our businesses remain robust in key segments and we expect to deliver sustainable growth, going forward."





## Corporate Announcement

Jubilant Life Sciences Limited (JLL), an integrated global Pharmaceuticals and Life Sciences company has announced that the Committee constituted on 26<sup>th</sup> July, 2019 to consider the option of reorganizing the businesses of the company has recommended the following:

- i. Demerger of the Life Science Ingredients (LSI) business with an objective to create separate and focused entities for Pharmaceuticals & Life Science Ingredients businesses respectively to unlock shareholder value;
- ii. Amalgamation of Promoter shareholding companies into JLL with an objective to simplify the holding structure of the promoters with no change in ownership percentage and number of shares of the promoters in JLL.

The Board, after due evaluation and consideration, has approved the recommendations of the Committee. The composite scheme of arrangement will be filed with the National Company Law Tribunal (NCLT) for its approval. Post the scheme becoming effective, the Life Science Ingredients business will stand demerged into the resulting entity, which will be listed on NSE and BSE with a mirror shareholding of JLL.

### **Commenting on the development, Mr Shyam S Bhartia, Chairman and Mr Hari S Bhartia, Co-Chairman & Managing Director of JLL said:**

“We believe that the proposed demerger will ensure depth and focus to adopt strategies necessary for growth, unlock shareholder value with direct ownership and attract focused investors in each of the business entities. Also the proposed Amalgamations will simplify the promoter shareholding structure of JLL.”

### **Structure post demerger**

1. The Pharmaceutical entity will have three businesses viz.-
  - Pharma business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectibles & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India,
  - Drug Discovery Services (DDS) business through Jubilant Biosys Limited & Jubilant Chemsys Limited provides innovation and collaborative research through two world class research centers in India, and
  - Proprietary Drug Discovery business through Jubilant Therapeutics, a semi-virtual biopharma company, with a business model of targeting small molecule therapies in the area of oncology and auto-immune disorders

The consolidated Pharmaceutical entity had revenue of Rs 5,567 crore with EBITDA of Rs 1,353 crore in FY19.

2. The demerged LSI business along with its subsidiaries into the resulting entity will engage in Specialty Intermediates, Nutritional Products and Life Science Chemicals through five manufacturing facilities in India.

The consolidated revenue of LSI business was Rs 3,553 crore with EBITDA of Rs 422 crore in FY19.



## Q2'FY20 Highlights

### Consolidated

- Consolidated revenue flat at Rs 2,266 Crore as compared with Q2'FY19
- EBITDA at Rs 481 Crore up by 6% YoY with margin of 21.2%.
- Adjusted EBITDA, after adjusting for one-off expenses of Rs 23 Crore, at Rs 504 Crore up 9% YoY with margin of 22.2%
- Finance costs at Rs. 72 Crore up from Rs 63 Crore in Q2 last year and lower 1% QoQ
- PAT at Rs. 249 Crore up 19% YoY with EPS at Rs. 15.7 for Re. 1 FV vs. Rs 13.5 for Re. 1 FV in Q2 last year
- Capital Expenditure of Rs. 148 Crore
- Gross Debt at Rs. 4,594 Crore and Net debt at Rs. 3,231 Crore
  - Net debt at Rs. 3,145 Crore on a constant currency basis
  - Average blended interest rate for H1'FY20 @ 6.08%; INR loans @ 8.28% and USD loans @ 5.33%

### Segment Wise Analysis

#### A. Pharmaceuticals Segment

- Pharmaceuticals segment's revenue up 9% YoY in Q2'FY20 to Rs. 1,452 Crore contributing 64% to the company's revenue as compared to 59% in Q2'FY19
- EBITDA of Rs. 386 Crore up 7% YoY and 17% QoQ with margin of 26.6% vs. 27% in Q2'FY19
- Adjusted EBITDA, after adjusting for one-off expenses of Rs 23 Crore, at Rs 409 Crore up 11% YoY with margin of 28.1%
- R&D spent during the quarter of Rs. 57 Crore – 3.9% to segment sales. R&D debited to P&L is Rs. 53 Crore – 3.7% to segment sales

#### B. Life Science Ingredients Segment

- LSI revenue at Rs. 753 Crore, down 15% YoY, contributing 33% to the company's revenues
- EBITDA at Rs 91 Crore down 16% YoY with a margin of 12.1% vs. 12.3% in Q2'FY19

#### C. Drug Discovery & Development Solutions Segment

- Revenues at Rs. 61 Crore up 20% YoY
- EBITDA was at Rs. 13 Crore up from Rs 8 Crore in Q2'FY19

## H1'FY20 Highlights

### Consolidated

- Consolidated revenue at Rs 4,448 Crore up 2% YoY
- EBITDA at Rs 925 Crore up 3% YoY with margin of 20.8% as compared with 20.7% last year
- Adjusted EBITDA, after adjusting for one-off expenses of Rs 71 Crore, at Rs 996 Crore up 9% YoY with margin of 22.4%
- Finance costs at Rs. 144 Crore up from Rs 135 Crore in H1'FY19
- PAT at Rs. 434 Crore up 5% YoY with EPS at Rs. 27.3 vs. Rs 26.5 in H1 last year
- Capital Expenditure of Rs. 317 Crore

### Segment Wise Analysis

#### D. Pharmaceuticals Segment

- Pharmaceuticals segment's revenue up 10% YoY in H1'FY20 to Rs. 2,781 Crore
- EBITDA of Rs. 716 Crore vs. Rs 699 Crore in H1'FY19 with margin of 25.7% vs 27.7% in H1'FY19
- Adjusted EBITDA, after adjusting for one-off expenses of Rs 63 Crore, at Rs 778 Crore up 9% YoY with margin of 28% vs. 28.3% last year
- R&D spent during H1 at Rs. 113 Crore – 4.1% to segment sales. R&D debited to P&L is Rs. 102 Crore – 3.7% to segment sales

#### E. Life Science Ingredients Segment

- LSI revenue at Rs. 1,559 Crore, down 10% YoY
- EBITDA at Rs 213 Crore down 3% YoY with a margin of 13.7% vs. 12.6% in H1'FY19
- Adjusted EBITDA, after adjusting for one-off expenses of Rs 9 Crore, at Rs 221 Crore up 1% YoY with margin of 14.2% vs 12.6% last year

#### F. Drug Discovery & Development Solutions Segment

- Revenues at Rs. 109 Crore up 14% YoY
- EBITDA was at Rs. 21 Crore up from Rs. 14 Crore in H1'FY19.

Particulars <sup>1</sup>	Q2'FY19	Q2'FY20	YoY Growth	H1'FY19	H1'FY20	YoY Growth
<b>Total Revenue from Operations</b>	<b>2,269</b>	<b>2,266</b>	<b>(0%)</b>	<b>4,348</b>	<b>4,448</b>	<b>2%</b>
Pharmaceuticals	1,332	1,452	9%	2,519	2,781	10%
Life Science Ingredients	887	753	(15%)	1,734	1,559	(10%)
Drug Discovery & Development Solutions	50	61	20%	95	109	14%
<b>Total Expenditure</b>	<b>1,819</b>	<b>1,797</b>	<b>(1%)</b>	<b>3,460</b>	<b>3,545</b>	<b>2%</b>
Other Income	4	12	220%	13	22	65%
<b>Segment EBITDA</b>	<b>478</b>	<b>490</b>	<b>3%</b>	<b>931</b>	<b>950</b>	<b>2%</b>
Pharmaceuticals	360	386	7%	699	716	2%
Life Science Ingredients	109	91	(16%)	218	213	(3%)
Drug Discovery & Development Solutions	8	13	56%	14	21	54%
Corporate (Expenses)/Income	(24)	(9)		(30)	(25)	
<b>Reported EBITDA</b>	<b>454</b>	<b>481</b>	<b>6%</b>	<b>901</b>	<b>925</b>	<b>3%</b>
Depreciation and Amortization	89	117	31%	177	220	24%
Finance Cost	63	72	14%	135	144	6%
<b>Profit before Tax</b>	<b>302</b>	<b>292</b>	<b>(3%)</b>	<b>588</b>	<b>561</b>	<b>(5%)</b>
Tax Expenses (Net)	92	43	(53%)	178	127	(29%)
Minority Interest	(1)	0	-	(3)	0	-
<b>PAT</b>	<b>210</b>	<b>249</b>	<b>19%</b>	<b>413</b>	<b>434</b>	<b>5%</b>
<b>Earnings Per Share - Face Value Re. 1 (Rs.)</b>	<b>13.5</b>	<b>15.7</b>	<b>16%</b>	<b>26.5</b>	<b>27.3</b>	<b>3%</b>
<b>Segment EBITDA Margins</b>	<b>21.0%</b>	<b>21.6%</b>		<b>21.4%</b>	<b>21.4%</b>	
Pharmaceuticals	27.0%	26.6%		27.7%	25.7%	
Life Science Ingredients	12.3%	12.1%		12.6%	13.7%	
Drug Discovery & Development Solutions	16.6%	21.5%		14.7%	19.8%	
<b>Reported EBITDA Margin</b>	<b>20.0%</b>	<b>21.2%</b>		<b>20.7%</b>	<b>20.8%</b>	
<b>Net Margin</b>	<b>9.3%</b>	<b>11.0%</b>		<b>9.5%</b>	<b>9.8%</b>	

### Earnings Call details

The company will host earnings call at 5.00 PM IST on October 25, 2019, to discuss the performance and answer questions from participants.

Participants can dial-in on the numbers below

Primary Number: + 91 22 6280 1141 / + 91 22 7115 8042

Local Access Number: +91-7045671221 (Available all over India)

Toll Free Numbers:

USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448



## About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery & Development Solutions businesses. Pharma business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectibles & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through five manufacturing facilities in India. Drug Discovery & Development Solutions comprises Drug Discovery Services (DDS) business through Jubilant Biosys Limited & Jubilant Chemsys Limited and Proprietary Drug Discovery business through Jubilant Therapeutics. DDS provides innovation and collaborative research through two world class research centers in India and Proprietary Drug Discovery is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Life Sciences Limited has a team of around 7,700 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

## For more information, please contact:

### For Investors

Ravi Agrawal / Vineet Mayer  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002 / 1021  
E-mail: [ravi.agrawal@jubl.com](mailto:ravi.agrawal@jubl.com)  
[vineet.mayer@jubl.com](mailto:vineet.mayer@jubl.com)

Siddharth Rangnekar  
CDR India  
Ph: +91 22 6645 1209  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

### For Media

Sudhakar Safaya  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1034  
E-mail: [sudhakar.safaya@jubl.com](mailto:sudhakar.safaya@jubl.com)

Gaurav Kashyap  
Perfect Relations  
Ph: +91 9871298413  
E-mail: [gaurav.kashyap@perfectrelations.com](mailto:gaurav.kashyap@perfectrelations.com)

## Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.



***JUBILANT***  
***LIFESCIENCES***

**Financial Results**  
**Quarter Ended Sep 30, 2019**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

**NOTES:**

1. *All Financial Data in this presentation is derived from the limited reviewed Financial Results of the Consolidated entity*
2. *The numbers for the quarter have been reclassified and regrouped wherever necessary*
3. *Closing Exchange Rate for USD 1 at Rs. 70.88 as on Sep 30'19, Rs 69.16 as on Mar 31'19 and Rs.72.49 as on Sep 30'18*

# Conference Call Details

**Date : October 25, 2019**

**Time : 05:00 pm IST**

<b>Primary Number:</b>	<b>+ 91 22 6280 1141</b> <b>+ 91 22 7115 8042</b>
<b>Local Access Number:</b>	<b>+91-7045671221</b> <b>Available all over India.</b>
<b>Toll Free Number:</b>	<b>USA: 1 866 746 2133</b> <b>UK: 0 808 101 1573</b> <b>Singapore: 800 101 2045</b> <b>Hong Kong: 800 964 448</b>

**Replay from : October 25 to November 2, 2019**

**Dial in No.: +91 22 7194 5757**

**Playback ID: 27287#**



## JUBILANT Q2'FY20 PERFORMANCE

**Revenue flat at Rs. 2,266 Crore vs. Q2'FY19; EBITDA at Rs 481 Crore up 6% YoY and 8% QoQ  
PAT at Rs 249 Crore up 19% YoY and 35% QoQ with EPS of Rs. 15.7 per share vs. Rs 13.5 per share last year**

**Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences Ltd. said:**

“We witnessed steady performance in revenue and improvement in operating profits in Q2'FY20 both on a YoY basis and sequentially.

Pharmaceutical segment revenues grew 9% both in YoY and QoQ, led by growth in all key businesses. EBITDA growth of 7% YoY and 17% QoQ with margin at 26.6%. Adjusted EBITDA of Pharmaceutical segment was 11% higher YoY with a margin of 28.1% after adjusting for one-off expenses of Rs 23 Crore related to site remediation and litigation expenses.

In the Life Science Ingredients (LSI) segment while we witnessed good growth in Specialty Intermediates and Nutritional Products businesses, the overall revenue was down 15% YoY due to lower input prices of acetic acid and higher molasses prices in the Life Sciences Chemical business.

The Drug Discovery Services business grew 20%. In view of the strong demand being witnessed, we are making significant investments in this business to double capacities over the next 2-3 years.

Our Proprietary Drug Discovery business under Jubilant Therapeutics is a semi virtual biopharma business. We are currently working on seven programs targeting small molecule therapies in the area of oncology and auto-immune disorders with potential to fast track promising assets from discovery to clinical stage.

Demand conditions for our businesses remain robust in key segments and we expect to deliver sustainable growth, going forward.”

# Corporate Announcement

Jubilant Life Sciences Limited (JLL), an integrated global Pharmaceuticals and Life Sciences company has announced that the Committee constituted on 26<sup>th</sup> July, 2019 to consider the option of reorganizing the businesses of the company has recommended the following:

- i. Demerger of the Life Science Ingredients (LSI) business with an objective to create separate and focused entities for Pharmaceuticals & Life Science Ingredients businesses respectively to unlock shareholder value;
- ii. Amalgamation of Promoter shareholding companies into JLL with an objective to simplify the holding structure of the promoters with no change in ownership percentage and number of shares of the promoters in JLL.

The Board, after due evaluation and consideration, has approved the recommendations of the Committee. The composite scheme of arrangement will be filed with the National Company Law Tribunal (NCLT) for its approval. Post the scheme becoming effective, the Life Science Ingredients business will stand demerged into the resulting entity, which will be listed on NSE and BSE with a mirror shareholding of JLL.

Commenting on the development, Mr Shyam S Bhartia, Chairman and Mr Hari S Bhartia, Co-Chairman & Managing Director of JLL said:

“We believe that the proposed demerger will ensure depth and focus to adopt strategies necessary for growth, unlock shareholder value with direct ownership and attract focused investors in each of the business entities. Also the proposed Amalgamations will simplify the promoter shareholding structure of JLL.”

## **Structure post demerger**

1. The Pharmaceutical entity will have three businesses viz.-
  - Pharma business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectibles & Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India,
  - Drug Discovery Services (DDS) business through Jubilant Biosys Limited & Jubilant Chemsys Limited provides innovation and collaborative research through two world class research centers in India, and
  - Proprietary Drug Discovery business through Jubilant Therapeutics, a semi-virtual biopharma company, with a business model of targeting small molecule therapies in the area of oncology and auto-immune disorders

The consolidated Pharmaceutical entity had revenue of Rs 5,567 crore with EBITDA of Rs 1,353 crore in FY19.

2. The demerged LSI business along with its subsidiaries into the resulting entity will engage in Specialty Intermediates, Nutritional Products and Life Science Chemicals through five manufacturing facilities in India.

The consolidated revenue of LSI business was Rs 3,553 crore with EBITDA of Rs 422 crore in FY19.

# Rationale of Demerger

- ❖ Create focused, distinct and separate entities for Pharmaceuticals and LSI business undertakings leading to greater operational efficiencies with dedicated management structure.
- ❖ These distinct business undertakings will enable strategic growth with optimal capital structure and deployment of cash flows for investments, capital expenditure and dividends.
- ❖ Unlock shareholder value with direct ownership and attract focused investors in each of the business entities.

# Rationale of Amalgamation

- ❖ Currently, a significant portion of the Promoters' shareholding in Jubilant Life Sciences is held through a multi-tier structure. The proposed Amalgamations will result in a simplified structure directly identifiable with the Promoters.
- ❖ The current regulatory requirements discourage multi-tier structures and hence, this simplification of promoter's shareholding would facilitate ease of regulatory compliance.
- ❖ The shareholders of merging promoter entities shall be issued same number of shares of JLL as held on the effective date pursuant to the Amalgamations. Hence, no change in aggregate promoters shareholding.
- ❖ All costs, charges, expenses and taxes/duties arising out of or in connection with the Amalgamations shall be borne by the Promoters.
- ❖ The merging entities shall have no liabilities on the effective date. The Promoters shall fully indemnify JLL for any and every liability, claim, demand of the merging entities of present, past and future which may devolve on JLL on account of the Amalgamations.


# Q2'FY20 Results Analysis

# JLL – Q2'FY20 Financial Highlights



Particulars <sup>1</sup>	Q2'FY19	Q2'FY20	YoY Change (%)
<b>Revenue</b>			
Pharmaceuticals <sup>2</sup>	1,332	1,452	9%
Life Science Ingredients	887	753	(15%)
Drug Discovery & Development Solutions <sup>3</sup>	50	61	20%
<b>Total Revenue from Operations</b>	<b>2,269</b>	<b>2,266</b>	<b>(0%)</b>
<b>EBITDA</b>			
Pharmaceuticals <sup>2</sup>	360	386	7%
Life Science Ingredients	109	91	(16%)
Drug Discovery & Development Solutions	8	13	56%
Unallocated Corporate Expenses	(24)	(9)	
<b>Reported EBITDA</b>	<b>454</b>	<b>481</b>	<b>6%</b>
<b>Adjusted EBITDA</b>	<b>462</b>	<b>504</b>	<b>9%</b>
PAT	210	249	19%
EPS	13.5	15.7	16%
<b>EBITDA Margins</b>			
Pharmaceuticals	27.0%	26.6%	
Life Science Ingredients	12.3%	12.1%	
Drug Discovery & Development Solutions	16.6%	21.5%	
<b>Reported EBITDA</b>	<b>20.0%</b>	<b>21.2%</b>	
<b>Adjusted EBITDA</b>	<b>20.4%</b>	<b>22.2%</b>	

## Geography Wise Revenue<sup>1</sup>



1. All figures are in Rs Crore unless otherwise stated

2. Pharmaceuticals segment includes India Branded Pharmaceuticals business under the Generics segment

3. Drug Discovery & Development Solutions include the Drug Discovery Services (Jubilant Biosys & Jubilant Chemsys) business and Proprietary Drug Discovery business (Jubilant Therapeutics)

- Revenue flat at Rs 2,266 Crore vs. Q2'FY19
  - Pharmaceuticals revenue at Rs 1,452 Crore, up 9% YoY, contributing 64% to revenue
  - LSI revenue at Rs 753 Crore down 15% YoY, contributing 33% to revenue
  - Drug Discovery & Development Solutions (DDDS) revenue was at Rs 61 Crore up 20% YoY
- Reported EBITDA at Rs 481 Crore up 6% YoY. EBITDA margin at 21.2% up from 20% in Q2 last year
  - Pharmaceuticals EBITDA at Rs 386 Crore up 7% YoY with a margin of 26.6% as compared to 27% in Q2 last year
  - LSI EBITDA at Rs 91 Crore down from Rs 109 Crore in Q2'FY19; Q2'FY20 margin at 12.1% as compared to 12.3% in Q2 last year
  - DDDS EBITDA at Rs 13 Crore up from Rs 8 Crore in Q2 last year; Q2'FY20 margin at 21.5% up from 16.6% in Q2 last year
    - Drug Discovery Services EBITDA was at Rs 18 Crore up from Rs 8 Crore in Q2'FY19 with margins of 29.4%
    - Proprietary Drug Discovery is currently working on seven programs targeting small molecules with potential to fast track promising assets
- Adjusted EBITDA after one-off expenses at Rs 504 Crore vs. Rs 462 Crore in Q2 last year, growth of 9% YoY. Adjusted EBITDA margin for the quarter is 22.2% vs. 20.4% in Q2 last year
- Finance costs at Rs 72 Crore up 14% YoY and lower by 1% QoQ
- Net Profit at Rs 249 Crore up 19% YoY and 35% QoQ. EPS of Rs 15.7 vs. Rs 13.5 in Q2 last year
- Capex in Q2'FY20 of Rs 148 Crore
- Net debt lower by Rs 149 Crore during the quarter



# Q2'FY20 Adjusted Earnings

## Consol EBITDA

S. No.	Particulars	Q2'FY19	Q2'FY20	% Change YoY	Rs Crore
1	Reported EBITDA	454	481	6%	
2	One-off Adjustments	8	23		
3	Adjusted EBITDA	462	504	9%	
4	Reported EBITDA Margin	20.0%	21.2%		
5	Adjusted EBITDA Margin	20.4%	22.2%		

## One-off Expenses

S. No.	Particulars	Q2'FY19	Q2'FY20
1	Site remediation and non-supply penalties due to Roorkee Warning Letter	0	17
2	Litigation Expense	8	6
	<b>Total One-Off Expenses</b>	<b>8</b>	<b>23</b>


# Pharmaceuticals Segment Highlights – Q2'FY20 (1/2)



Particulars <sup>1</sup>	Q2'FY19	Q2'FY20	% Change
Revenue	1,332	1,452	9%
Specialty Pharma	712	743	4%
CDMO	372	411	10%
Generics	248	298	20%
Reported EBITDA	360	386	7%
Adjusted EBITDA	368	409	11%
Reported EBITDA Margin (%)	27.0%	26.6%	
Adjusted EBITDA Margin (%)	27.6%	28.1%	

- Pharmaceuticals revenue at Rs 1,452 Crore, up 9% both YoY and QoQ
  - Healthy growth in all key revenue segments led by 20% YoY growth in Generics and 10% growth in CDMO
  - Revenue from North America grew 11% YoY, while that from ROW was up 26% YoY.
- Pharmaceuticals EBITDA at Rs 386 Crore up 7% YoY with a margin of 26.6% as compared to 27% in Q2'FY19. Sequentially Pharma EBITDA was up 17% during the quarter with margin improvement by 173 bps
- Pharmaceuticals adjusted EBITDA at Rs 409 Crore up 11% YoY with a margin of 28.1% as compared to 27.6% in Q2 last year
  - One-off expenses of Rs 23 Crore related to related to site remediation and litigation expenses

## Geography Wise Revenue<sup>1</sup>



## Specialty Pharmaceuticals<sup>2</sup> (51% of Pharma Revenues)

- Growth in Radiopharma business was driven by higher volumes in Ruby-Fill® and other products
- Revenue growth witnessed in Allergy business both YoY and sequentially due to higher volumes in venom

1. All figures are in Rs Crore unless otherwise stated

2. Specialty Pharmaceuticals comprises Radiopharma and Allergy Therapy Products businesses

# Pharmaceuticals Segment Highlights – Q2'FY20 (2/2)



## USFDA Inspection Details

Facility	Last Inspection
Montreal, CMO	May, 2018
Montreal, Radiopharma	Sep, 2017
Salisbury	May, 2018
Spokane	July, 2019
Roorkee	Aug, 2018
Nanjangud	Dec, 2018

## Product Pipeline as on Sep 30, 2019

Dosage (Orals) (#)			
	Filings	Approved	Pending
US	96	61	35
Canada	23	23	0
Europe	36	33	3
ROW	41	36	5
Steriles (#)			
	Filings	Approved	Pending
US	15	13	2
Canada	17	16	1
Europe	4	4	0
ROW	9	9	0

## CDMO<sup>1</sup>

- Revenue up by 10% YoY and 19% QoQ to Rs 411 Crore

## CMO

- Growth in CMO business led by higher volumes from existing customers
- Initiatives taken to increase total capacity by over 30% with annual potential revenues of around USD 30 million
  - Increased shifts to 24x7 on Line 2 from Q3'FY19. Plan to increase shifts to 24x7 on line 1 from Q3'FY20 onwards
  - New Lyo equipment installed at line 2 at the Spokane facility with validations underway, commercialisation expected during H2'FY20

## API

- Revenue growth witnessed on account of higher sales of existing products and better pricing, which was partly offset by lower volumes of valsartan
  - Lower volumes were due to additional quality checks on all input raw materials to meet enhanced regulatory requirements
- Company working diligently with the US FDA and Health Canada, regarding the resolution of the Official Action Indicated (OAI) in Nanjangud

## Generics<sup>2</sup>

- Revenue growth of 20% YoY and 15% QoQ driven by both higher volumes and better prices
- Roorkee WL – Remediation process progressing well in consultation with 3rd party consultants to address US FDA observations.

**R&D** spent during the quarter of Rs. 57 Crore – 3.9% to segment sales. R&D debited to P&L is Rs. 53 Crore – 3.7% to segment sales


1. Contract Development and Manufacturing (CDMO) business comprises CMO and API businesses

2. Generics business refers to the company's solid dosage formulations business and the India Branded Pharmaceuticals business


# LSI Segment Highlights – Q2'FY20

Particulars <sup>1</sup>	Q2'FY19	Q2'FY20	% Change
Revenue	887	753	(15%)
Specialty Intermediates	196	259	32%
Nutritional Products	107	113	6%
Life Science Chemicals	584	380	(35%)
Reported EBITDA	109	91	(16%)
Reported EBITDA Margin (%)	12.3%	12.1%	

## Revenue Breakup by End-Use Industries



## Geography Wise Revenue<sup>1</sup>



- LSI revenue at Rs 753 Crore, down 15% YoY and 7% QoQ mainly due to
  - Strong growth in Specialty Intermediates and Nutritional Products
  - Lower revenues in Life Science Chemicals (LSC) from lower input prices
- EBITDA at Rs 91 Crore down 16% YoY and 25% QoQ with margin of 12.1% as compared to 12.3% in Q2'FY19
  - Strong growth in profitability in Specialty Intermediates and Nutritional Products businesses
  - LSC profitability impacted due to higher molasses prices and lower contribution in acetyl business due to supply demand normalization

### Specialty Intermediates

- Revenue up 32% YoY led by strong demand and better prices in key products such as Pyridine, Beta and Pyridine derivatives
- Positive traction for new pyridine derivatives launched in last one year

### Nutritional Products

- Revenue up 6% YoY led by better prices of Vitamin B3
- Demand scenario expected to pick up in H2'FY20

### Life Science Chemicals


- Revenue down 35% YoY due to significant drop in Acetic acid price by \$280/MT over Q2'FY19, which led to price correction of Life sciences chemicals products.
- Demand for acetic anhydride remained subdued during the quarter

# Drug Discovery & Development Solutions – Q2'FY20



Particulars <sup>1</sup>	Q2'FY19	Q2'FY20	% Change
Revenue	50	61	20%
Drug Discovery Services	50	61	20%
Proprietary Drug Discovery	0	0	-
Reported EBITDA	8	13	56%
Drug Discovery Services	8	18	113%
Proprietary Drug Discovery	0	(5)	-
Reported EBITDA Margin (%)	16.6%	21.5%	
Drug Discovery Services	16.6%	29.4%	

## Geography Wise Revenue<sup>1</sup>



- Drug Discovery & Development Solutions (DDDS) comprises
  - Drug Discovery Services business through Jubilant Biosys Limited & Jubilant Chemsys Limited which provides innovation and collaborative research through two world class research centers in India
  - Proprietary Drug Discovery business through Jubilant Therapeutics, a semi-virtual biopharma company, with a business model of targeting small molecule therapies in the area of oncology and auto-immune disorders
- DDDS revenue up 20% YoY to Rs 61 Crore led by growth in Drug Discovery Services business
  - Drug Discovery Services business grew by 20% driven by higher demand from Biotech companies for Integrated Services, DMPK, Biology, Chemistry & Scale-up
  - In our Proprietary Drug Discovery business we have seven programs at different stages with potential to partner and/or fast track from discovery to clinical stage
  - Revenue from North America up 17% YoY, while that from Europe & Japan was higher by 28% YoY
- EBITDA at Rs 13 Crore up 56% YoY with margin of 21.5%
  - Drug Discovery Services EBITDA increased to Rs 18 Crore from Rs 8 Crore last year, growth of 113% YoY. Margin improvement to 29.4% from 16.6% last year

1. All figures are in Rs Crore unless otherwise stated

# Proprietary Drug Discovery (Jubilant Therapeutics)



- Jubilant Therapeutics, a subsidiary of Jubilant Life Sciences for proprietary innovation, is a capital efficient, semi-virtual biopharma with agile business model and asset specific subsidiaries for creative partnerships.
- The company's core strategy is to develop novel and targeted small molecule therapies to address patients' unmet medical need in the area of Oncology and Auto-Immune disorders.

## Status of Proprietary Programs


Programs	Indication	Pathway	Current status	Stage/remarks
<b>BRD4</b>	Liquid and solid tumours	Epigenetics	Preclinical	Partnered with Checkpoint Therapeutics in 2016 at lead stage with potential milestones. Successfully completed toxicology studies with expected Phase I initiation in FY21.
<b>LSD1/HDAC6 –Dual Inhibitor</b>	MDS/AML, selected solid tumors	Epigenetics	Pre-clinical	Novel dual first in class epigenetic inhibitors of LSD1/HDAC6 to address unmet needs in liquid cancers like acute myeloid leukaemia (AML). Pre-IND studies including CMC initiated to enable Phase I clinical trial in FY21.
<b>mEGFR</b>	NSCLC	Kinase	Lead optimization	Addresses unmet need of patients developing resistance to kinase inhibitors. Lead optimization in FY20 and ready for partnering.
<b>PDL-1</b>	Broad spectrum of Cancer	Immuno-oncology	Lead optimisation	Small molecule therapy with comparable efficacy to large molecules with potentially better safety profiles in initial studies. Further optimization and characterization of lead molecule expected to be completed in FY20.
<b>PAD4</b>	Inflammation and auto immune disorder	Epigenetics	Lead optimisation	Potential to address unmet needs in multiple auto-immune disorders like rheumatoid arthritis, psoriasis and atopic dermatitis. Demonstrated efficacy in various auto immune-disorders in animal models. Preclinical candidate selection expected in FY20.
<b>PRMT5</b>	Lymphoma	Epigenetics	Lead identification	Completion of lead identification and characterization expected in FY 20.
<b>Undisclosed target</b>	AML, prostate cancer	Epigenetics	Lead identification	Addresses patients who are refractive to current line of therapy. Expected completion of lead identification in FY20.

# H1'FY20 Results Analysis

# JLL – H1'FY20 Financial Highlights

Particulars <sup>1</sup>	H1'FY19	H1'FY20	YoY Change (%)
<b>Revenue</b>			
Pharmaceuticals <sup>2</sup>	2,519	2,781	10%
Life Science Ingredients	1,734	1,559	(10%)
Drug Discovery & Development Solutions <sup>3</sup>	95	109	14%
<b>Total Revenue from Operations</b>	<b>4,348</b>	<b>4,448</b>	<b>2%</b>
<b>EBITDA</b>			
Pharmaceuticals <sup>2</sup>	699	716	2%
Life Science Ingredients	218	213	(3%)
Drug Discovery & Development Solutions	14	21	54%
Unallocated Corporate Expenses	(30)	(25)	-
<b>Reported EBITDA</b>	<b>901</b>	<b>925</b>	<b>3%</b>
<b>Adjusted EBITDA</b>	<b>914</b>	<b>996</b>	<b>9%</b>
PAT	413	434	5%
EPS	26.5	27.3	3%
<b>EBITDA Margins</b>			
Pharmaceuticals	27.7%	25.7%	
Life Science Ingredients	12.6%	13.7%	
Drug Discovery & Development Solutions	14.7%	19.8%	
Reported EBITDA	20.7%	20.8%	
Adjusted EBITDA	21.0%	22.4%	

## Geography Wise Revenue<sup>1</sup>



- Revenue at Rs 4,448 Crore up 2% from Rs 4,348 Crore in H1'FY19
  - Pharmaceuticals revenue at Rs 2,781 Crore, up 10% YoY, contributing 63% to revenue
  - LSI revenue at Rs 1,559 Crore down 10% YoY, contributing 35% to revenue
  - Drug Discovery & Development Solutions (DDDS) revenue at Rs 109 Crore up 14% YoY
- Reported EBITDA at Rs 925 Crore up 3% YoY. EBITDA margin at 20.8% similar to H1 last year
  - Pharmaceuticals EBITDA at Rs 716 Crore up 2% YoY with a margin of 25.7% as compared to 27.7% in H1 last year
  - LSI EBITDA at Rs 213 Crore as compared to Rs 218 Crore in H1'FY19; H1'FY20 margin at 13.7% as compared to 12.6% in H1 last year
  - DDDS EBITDA at Rs 21 Crore up from Rs 14 Crore in H1 last year; H1'FY20 margin at 19.8% as compared with 14.7% in H1 last year
- Adjusted EBITDA after one-off expenses at Rs 996 Crore vs. Rs 914 Crore in H1 last year, growth of 9% YoY. Adjusted EBITDA margin in H1 was 22.4% vs. 21% in H1 last year
- Finance costs at Rs 144 Crore up 6% YoY
- Net Profit at Rs 434 Crore up 5% YoY. EPS of Rs 27.3 vs. Rs 26.5 in H1'FY19
- Capex in H1'FY20 of Rs 317 Crore
- Net debt lower by Rs 345 Crore during H1'FY20

1. All figures are in Rs Crore unless otherwise stated

2. Pharmaceuticals segment includes India Branded Pharmaceuticals business under the Generics segment

3. Drug Discovery & Development Solutions include the Drug Discovery Services (Biosys & Chemsys) business and Proprietary Drug Discovery business (Jubilant Therapeutics)



# H1'FY20 Adjusted Earnings

## Consol EBITDA

S. No.	Particulars	H1'FY19	H1'FY20	% Change YoY	Rs Crore
1	Reported EBITDA	901	925	3%	
2	One-off Adjustments	13	71		
3	Adjusted EBITDA	914	996	9%	
4	Reported EBITDA Margin	20.7%	20.8%		
5	Adjusted EBITDA Margin	21.0%	22.4%		


## One-off Expenses

S. No.	Particulars	H1'FY19	H1'FY20
1	Site remediation and non-supply penalties due to Roorkee Warning Letter	0	30
2	Litigation Expense	13	19
3	Exchange fluctuation on restatement of deposits	0	14
4	Donation	0	9
	<b>Total One-Off Expenses</b>	<b>13</b>	<b>71</b>

# Pharmaceuticals Segment Highlights – H1'FY20

Particulars <sup>1</sup>	H1'FY19	H1'FY20	% Change
Revenue	2,519	2,781	10%
Specialty Pharma	1,377	1,468	7%
CDMO	649	756	16%
Generics	493	557	13%
Reported EBITDA	699	716	2%
Adjusted EBITDA	712	778	9%
Reported EBITDA Margin (%)	27.7%	25.7%	
Adjusted EBITDA Margin (%)	28.3%	28.0%	

## Geography Wise Revenue<sup>1</sup>



- Pharmaceuticals revenue at Rs 2,781 Crore, up 10% YoY
  - Growth in all key revenue segments led by 16% YoY growth in CDMO and 13% growth in Generics
  - Revenue from North America grew 12% YoY, while that from ROW was up 20% YoY
- Pharmaceuticals EBITDA at Rs 716 Crore up 2% YoY with a margin of 25.7% as compared to 27.7% in H1'FY19.
- Pharmaceuticals Adjusted EBITDA at Rs 778 Crore up 9% YoY with a margin of 28% down from 28.3% in H1 last year
  - One-off expenses of Rs 63 Crore related to related to site remediation, litigation expenses and foreign exchange

### Specialty Pharma (53% of Pharma revenue)

- Radiopharma revenue was up due to higher volumes in-Ruby-Fill® and other key products and better prices
- Revenue growth witnessed in Allergy business due to higher volumes in venom and better prices

### CDMO

- Revenue up 16% to Rs 756 Crore
- Growth in CMO business led by strong demand witnessed from key customers, which was reflected by higher volumes as compared to last year
- API Revenue was flat amid better prices and lower volumes, mainly in Valsartan
  - Lower volumes were due to additional quality checks on all input raw materials to meet enhanced regulatory requirements

### Generics


- Revenue growth of 13% YoY due to better prices in some products which was offset by lower volumes

# LSI Segment Highlights – H1'FY20


## Life Science Chemicals Segment

Particulars <sup>1</sup>	H1'FY19	H1'FY20	% Change
Revenue	1,734	1,559	(10%)
Specialty Intermediates	431	539	25%
Nutritional Products	196	250	28%
Life Science Chemicals	1,107	770	(30%)
Reported EBITDA	218	213	(3%)
Adjusted EBITDA	218	221	1%
Reported EBITDA Margin (%)	12.6%	13.7%	
Adjusted EBITDA Margin (%)	12.6%	14.2%	

### Revenue Breakup by End-Use Industries



### Geography Wise Revenue<sup>1</sup>



- LSI revenue at Rs 1,559 Crore, down 10% YoY
- EBITDA at Rs 213 Crore down 3% YoY with margin of 13.7% as compared to 12.6% in H1'FY19. Adjusted EBITDA up 1% YoY to Rs 221 Crore in H1'FY20
  - Strong growth in profitability in Specialty Intermediates and Nutritional Products businesses
  - LSC profitability impacted due to higher molasses prices and lower contribution in acetyl business due to supply demand normalization

### Specialty Intermediates

- Revenue up 25% YoY led by strong demand and better prices in key products such as Pyridine, Beta and Pyridine derivatives
- Positive traction for new pyridine derivatives launched in last one year

### Nutritional Products

- Revenue up 28% YoY led by better prices of Vitamin B3
- Demand scenario expected to pick up in H2'FY20

### Life Science Chemicals


- Revenue down 30% YoY due to significant drop in Acetic acid price by \$268/MT over H1'FY19, which led to price correction of Life sciences chemicals products.

# Drug Discovery & Development Solutions – H1'FY20

Particulars <sup>1</sup>	H1'FY19	H1'FY20	% Change
Revenue	95	109	14%
Drug Discovery Services	95	109	14%
Proprietary Drug Discovery	0	0	-
Reported EBITDA	14	21	54%
Drug Discovery Services	14	29	106%
Proprietary Drug Discovery	0	(7)	-
Reported EBITDA Margin (%)	14.7%	19.8%	
Drug Discovery Services	14.7%	26.5%	

- DDDS segment revenue up 14% YoY to Rs 109 Crore led by growth in Drug Discovery Services business which was driven by higher demand from Biotech companies for Integrated Services, DMPK, Biology, Chemistry & Scale-up.
  - Revenue from North America up 18% YoY
- EBITDA at Rs 21 Crore higher up 54% YoY
  - Drug Discovery Services EBITDA increased to Rs 29 Crore up 106% YoY. Margin improvement to 26.5% from 14.6% last year

## Geography Wise Revenue<sup>1</sup>



# Debt Profile

Particulars	31/03/19	30/06/19	30/09/19
<b>Foreign Currency Loans</b>	<b>(\$ Mn)</b>	<b>(\$ Mn)</b>	<b>(\$ Mn)</b>
Subsidiaries	500	500	500
<b>Total</b>	<b>500</b>	<b>500</b>	<b>500</b>
<b>Rupee Loans</b>	<b>(Rs. Crs)</b>	<b>(Rs. Crs)</b>	<b>(Rs. Crs)</b>
Standalone	1,341	1,056	1,029
Subsidiaries	61	95	21
<b>Total</b>	<b>1,402</b>	<b>1,151</b>	<b>1,050</b>
<b>Gross Debt</b>	<b>(Rs. Crs)</b>	<b>(Rs. Crs)</b>	<b>(Rs. Crs)</b>
Standalone	1,341	1,056	1,029
Subsidiaries	3,519	3,546	3,565
<b>Total</b>	<b>4,860</b>	<b>4,602</b>	<b>4,594</b>
QoQ Change		(258)	(8)
Cumulative Change		(258)	(266)
Cash & Equivalent	1,370	1,316	1,363
<b>Net Debt</b>	<b>3,490</b>	<b>3,286</b>	<b>3,231</b>
Change in debt on account of exchange rate difference from March 31, 2019		7	(86)
Net Debt (On a Constant Currency Basis)	<b>3,490</b>	<b>3,293</b>	<b>3,145</b>
QoQ Change		(196)	(149)
Cumulative Change		(196)	(345)
Closing Exchange Rate (USD/Rs.)	69.16	69.02	70.88

- Net Debt reduction of Rs 149 Crore in Q2'FY20 and Rs 345 Crore in H1'FY20 as compared to March 31, 2019
- Average blended interest rate for H1'FY20 @ 6.08%; INR loans @ 8.28% and USD loans @ 5.33%

# Appendix

# Income Statement – Q2 & H1'FY20

Particulars <sup>1</sup>	Q2'FY19	Q2'FY20	YoY Growth	H1'FY19	H1'FY20	YoY Growth
<b>Total Revenue from Operations</b>	<b>2,269</b>	<b>2,266</b>	<b>(0%)</b>	<b>4,348</b>	<b>4,448</b>	<b>2%</b>
<b>Pharmaceuticals</b>	<b>1,332</b>	<b>1,452</b>	<b>9%</b>	<b>2,519</b>	<b>2,781</b>	<b>10%</b>
<b>Life Science Ingredients</b>	<b>887</b>	<b>753</b>	<b>(15%)</b>	<b>1,734</b>	<b>1,559</b>	<b>(10%)</b>
<b>Drug Discovery &amp; Development Solutions</b>	<b>50</b>	<b>61</b>	<b>20%</b>	<b>95</b>	<b>109</b>	<b>14%</b>
<b>Total Expenditure</b>	<b>1,819</b>	<b>1,797</b>	<b>(1%)</b>	<b>3,460</b>	<b>3,545</b>	<b>2%</b>
Other Income	4	12	220%	13	22	65%
<b>Segment EBITDA</b>	<b>478</b>	<b>490</b>	<b>3%</b>	<b>931</b>	<b>950</b>	<b>2%</b>
<b>Pharmaceuticals</b>	<b>360</b>	<b>386</b>	<b>7%</b>	<b>699</b>	<b>716</b>	<b>2%</b>
<b>Life Science Ingredients</b>	<b>109</b>	<b>91</b>	<b>(16%)</b>	<b>218</b>	<b>213</b>	<b>(3%)</b>
<b>Drug Discovery &amp; Development Solutions</b>	<b>8</b>	<b>13</b>	<b>56%</b>	<b>14</b>	<b>21</b>	<b>54%</b>
Corporate (Expenses)/Income	(24)	(9)		(30)	(25)	
<b>Reported EBITDA</b>	<b>454</b>	<b>481</b>	<b>6%</b>	<b>901</b>	<b>925</b>	<b>3%</b>
Depreciation and Amortization	89	117	31%	177	220	24%
Finance Cost	63	72	14%	135	144	6%
<b>Profit before Tax</b>	<b>302</b>	<b>292</b>	<b>(3%)</b>	<b>588</b>	<b>561</b>	<b>(5%)</b>
Tax Expenses (Net)	92	43	(53%)	178	127	(29%)
Minority Interest	(1)	0	-	(3)	0	-
<b>PAT</b>	<b>210</b>	<b>249</b>	<b>19%</b>	<b>413</b>	<b>434</b>	<b>5%</b>
<b>Earnings Per Share - Face Value Re. 1 (Rs.)</b>	<b>13.5</b>	<b>15.7</b>	<b>16%</b>	<b>26.5</b>	<b>27.3</b>	<b>3%</b>
<b>Segment EBITDA Margins</b>	<b>21.0%</b>	<b>21.6%</b>		<b>21.4%</b>	<b>21.4%</b>	
<b>Pharmaceuticals</b>	<b>27.0%</b>	<b>26.6%</b>		<b>27.7%</b>	<b>25.7%</b>	
<b>Life Science Ingredients</b>	<b>12.3%</b>	<b>12.1%</b>		<b>12.6%</b>	<b>13.7%</b>	
<b>Drug Discovery &amp; Development Solutions</b>	<b>16.6%</b>	<b>21.5%</b>		<b>14.7%</b>	<b>19.8%</b>	
<b>Reported EBITDA Margin</b>	<b>20.0%</b>	<b>21.2%</b>		<b>20.7%</b>	<b>20.8%</b>	
<b>Net Margin</b>	<b>9.3%</b>	<b>11.0%</b>		<b>9.5%</b>	<b>9.8%</b>	

## For Investors:

### **Ravi Agrawal/Vineet V Mayer**

Jubilant Life Sciences Limited

Ph: +91 120 436 1002 / 1021

E-mail: ravi.Agrawal@jubl.com

Vineet.mayer@jubl.com

### **Siddharth Rangnekar**

CDR India

Ph: +91 22 6645 1209

E-mail: siddharth@cdr-india.com

## For Media:

### **Sudhakar Safaya**

Jubilant Life Sciences Limited

Ph: +91 120 436 1034

E-mail: sudhakar.safaya@jubl.com

### **Gaurav Kashyap**

Perfect Relations

Ph: +91 9871298413

E-mail: gaurav.kashyap@perfectrelations.com

visit us at [www.jubl.com](http://www.jubl.com)